GlobeNewswire
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
📈
AI Sentiment
Highly Positive
9/10
Cognition Therapeutics Inc. News
Latest updates and market news for CGTX
1 news
Jan 4 - Jan 10, 2026
Page 1
Share this news page